Pyrrolopyrazine Kinase Inhibitors for Selective Cdc7 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer and cell proliferative disorders lack effective inhibitors for the protein kinase Cdc7, which is crucial for regulating DNA replication and is lethal to cancer cells but not normal cells, necessitating a targeted therapeutic approach.
Innovation Solution
Development of compounds with formula (I) that inhibit Cdc7, allowing for the administration of a therapeutically effective amount to treat cancer and decrease tumor volume by targeting the kinase's activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Cdc7 kinase is inhibited to treat cancer, then cancer cell proliferation is suppressed, but normal cell division is also affected
Solution Approach 1:
The patent applies local quality by creating kinase inhibitors with specific molecular structures (formula I compounds) that exhibit differential binding affinity to Cdc7 kinase in different cellular contexts. The inhibitors are designed to preferentially inhibit Cdc7 in cancer cells while allowing normal cells to maintain sufficient activity, achieving selective toxicity through molecular structure optimization rather than non-specific cell killing.
2Productivity
If Cdc7 kinase is inhibited to stop DNA replication, then tumor growth is reduced, but DNA replication is also blocked in normal cells
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical parameters of the inhibitor molecules (substituents at positions R1a, R1b, X, Y, and Z in formula I) to optimize binding affinity and selectivity. By adjusting molecular weight, functional groups, and spatial configuration, the compounds achieve enhanced inhibition of Cdc7 in cancer cells while maintaining lower inhibitory activity in normal cells, thus resolving the contradiction between tumor growth suppression and selective inhibition.
Data Source
AI summary
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts,wherein R1a, R1b, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.